AC
AXSM icon

Athanor Capital’s Axsome Therapeutics AXSM Stock Holding History

Athanor Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,367
Closed -$437K – 816
2020
Q4 		$437K Buy
+5,367
New +$401K 0.01% 499
2020
Q3 		– Sell
-11,047
Closed -$909K – 544
2020
Q2 		$909K Buy
+11,047
New +$850K 0.05% 209
2020
Q1 		– Sell
-3,100
Closed -$320K – 180
2019
Q4 		$320K Buy
+3,100
New +$125K 0.01% 302
2019
Q3 		– Sell
-9,200
Closed -$237K – 206
2019
Q2 		$237K Buy
+9,200
New +$184K 0.03% 121

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Athanor Capital's AXSM Position: Q1 2021 in Review

Athanor Capital sold out of Axsome Therapeutics (AXSM) in Q1 2021, closing a stake of 5,367 shares — an estimated $437K sold.

Athanor Capital first reported a position in AXSM in Q2 2019 and held it in 4 quarters. The position peaked at $909K in Q2 2020. 184 funds tracked by Wall St. Rank hold AXSM as of Q1 2021.

  • Athanor Capital reported no remaining Axsome Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 5,367 Axsome Therapeutics shares in Q1 2021, an estimated $437K.
  • Athanor Capital first reported a position in Axsome Therapeutics in Q2 2019 and held it in 4 quarters.
  • Athanor Capital's Axsome Therapeutics position peaked at $909K in Q2 2020.
  • 184 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.